Lilly Plans New Outcomes Study To Expand Jardiance Label
Zacks Investment Research | Jun 13, 2017 08:58AM ET
Eli Lilly and Company (NYSE:LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.
Last year, Lilly received an FDA approval to include cardiovascular risk reduction data from EMPA-REG OUTCOME study on the label of Jardiance. The updated label carrying cardiovascular indication was launched in Jan 2017 while the American Diabetes Association (ADA) has also restructured its diabetes treatment guidelines.
The European Commission had okayed the Jardiance label update for cardiovascular indication in 2016. Notably, Jardiance is the first and only medicine approved to reduce the risk of cardiovascular death in patients with type II diabetes.
Shares of Lilly have underperformed the Zacks classified Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.